These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 23863667

  • 1. [Survey of current status of adverse ocular reactions to paclitaxel and a retrospective analysis for aiding in early detection of adverse reactions].
    Noguchi Y, Nishimura R, Kawara H, Omori K, Matsumoto K, Tokuyama Y, Uchiyama K, Shimizu Y.
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):819-22. PubMed ID: 23863667
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
    Yoshimura T, Hirade K, Iihara H, Ishihara M, Komori Y, Okayasu S, Matsuura K, Yasuda T, Itoh Y.
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.
    Hirai Y, Hasumi K, Onose R, Kuramoto H, Kuzuya K, Hatae M, Ochiai K, Nozawa S, Noda K.
    Gynecol Oncol; 2004 Aug; 94(2):471-6. PubMed ID: 15297190
    [Abstract] [Full Text] [Related]

  • 5. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
    Kanbayashi Y, Hosokawa T, Kitawaki J, Taguchi T.
    Anticancer Res; 2013 Mar; 33(3):1153-6. PubMed ID: 23482795
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I, Szánthó A, Mayer A, Thurzó L, Pulay T.
    Orv Hetil; 2003 May 11; 144(19):919-24. PubMed ID: 12809068
    [Abstract] [Full Text] [Related]

  • 10. [Administration of nab-paclitaxel for 9 metastatic breast cancer patients].
    Sakaguchi K, Mizuta N, Imai A, Nakatsukasa K, Morita M, Soushi M, Taguchi T.
    Gan To Kagaku Ryoho; 2012 Jul 11; 39(7):1081-5. PubMed ID: 22790043
    [Abstract] [Full Text] [Related]

  • 11. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
    Noda K, Ikeda M, Kudo R, Nishiya I, Yajima A, Tanaka K, Kodama S, Takahashi T, Tokunaga A, Satoh I, Nozawa S, Taketani Y, Terashima Y, Isonishi S, Takeda Y, Nishijima M, Kuroshima Y, Fujii S, Izumi R, Tamaya T, Mori T, Okada H, Ogita S, Ozaki M, Hatae M.
    Gan To Kagaku Ryoho; 1996 Feb 11; 23(3):317-25. PubMed ID: 8712825
    [Abstract] [Full Text] [Related]

  • 12. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR, Boyd JH, Kim HJ, Dunphy CH, Harrison BR, Dunleavy TL, Rodriguez JJ, McDonough EM, Minster JR, Hilton JG.
    Cancer; 1997 May 15; 79(10):2016-23. PubMed ID: 9149030
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Semin Oncol; 1997 Dec 15; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Safety evaluation of adjuvant chemotherapy by weekly paclitaxel combined with weekly carboplatin in patients with postoperative non-small cell lung cancer].
    Hirose T, Nagao T, Kajikawa A, Sumi T, Sugimoto T, Hirose Y, Yoshida M, Kenzaki K.
    Gan To Kagaku Ryoho; 2007 Sep 15; 34(9):1397-400. PubMed ID: 17876136
    [Abstract] [Full Text] [Related]

  • 18. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR.
    Cancer; 2003 May 15; 97(10):2480-6. PubMed ID: 12733147
    [Abstract] [Full Text] [Related]

  • 19. Chronic administration of single-agent paclitaxel in gynecologic malignancies.
    Rohl J, Kushner D, Markman M.
    Gynecol Oncol; 2001 May 15; 81(2):201-5. PubMed ID: 11330950
    [Abstract] [Full Text] [Related]

  • 20. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K.
    Gan To Kagaku Ryoho; 2002 Feb 15; 29(2):221-6. PubMed ID: 11865627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.